A novel chemical entity (QBS10072S) has been developed for delivering a cytotoxic chemotherapeutic domain to GBM cells via LAT1 with a 50-fold higher selectivity than LAT2 [51]. This evidence concerns the gene SLC7A5 and glioblastoma.